Search Results - john+brognard

2 Results Sort By:
LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression
This technology includes the use of LZK and DLK inhibitors to be used for the treatment of head and neck squamous cell carcinoma (HNSCC) or lung squamous cell carcinoma (LSCC). Specifically, we demonstrate that inhibitors that can be repurposed to target LZK suppresses LZK kinase-dependent stabilization of MYC and activation of the PI3K/AKT pathway....
Published: 8/12/2024   |   Inventor(s): John Brognard, Rolf Swenson, Amy Funk, Carolyn Hitko, Katherine Nyswaner
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology
PIM-Targeted PROTACs
Abstract: Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers – including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical...
Published: 4/8/2024   |   Inventor(s): John Brognard, Rolf Swenson, Pedro Torres-Ayuso, Venkatareddy Sabbasani, Dawid Mehlich, Noel Warfel
Keywords(s): anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology